Mebendazole for Brain Tumours: Systematic Review Synthesizes 22 Studies (2026)
A 2026 systematic review evaluates mebendazole's preclinical and clinical evidence across glioblastoma, medulloblastoma, and meningioma, highlighting translational gaps.
By Sanare Lab · August 10, 2026 · 5 min read
Key Takeaway
A 2026 systematic review published in the British Journal of Clinical Pharmacology synthesizes 22 studies on mebendazole (MBZ) for primary brain tumours. Preclinical work across glioblastoma, diffuse midline glioma, medulloblastoma, and meningioma demonstrates consistent tumour growth suppression via microtubule depolymerization, kinase inhibition, angiogenesis blockade, and Hedgehog pathway interference. However, clinical evidence of efficacy remains modest, inconsistent, and inconclusive. The review concludes that further well-designed comparative trials with clear formulation reporting are needed.
Mebendazole, a benzimidazole anthelmintic with decades of clinical use against parasitic infections, has emerged as a compelling repurposing candidate for primary brain tumours. Its appeal lies in a unique combination of multimodal anticancer actions and documented central nervous system (CNS) penetrance — a critical requirement for any drug targeting brain malignancies. A 2026 systematic review published in the British Journal of Clinical Pharmacology provides the most comprehensive synthesis to date of mebendazole's preclinical and clinical evidence in neuro-oncology.
For patients exploring repurposed drug protocols for brain tumours, this review offers important insights into both the promise and the limitations of mebendazole. Our protocol dosing workspace provides tools to help evaluate dosing considerations. For related information on the benzimidazole family in brain cancer, see our dedicated guide on fenbendazole for brain cancer and glioblastoma. The broader Marik protocol also incorporates mebendazole alongside ivermectin as part of a metabolic therapy approach.
Systematic Review Methodology
The 2026 review was conducted in accordance with the Joanna Briggs Institute (JBI) methodology, a rigorous framework for systematic reviews. The authors searched PubMed, EMBASE, SCOPUS, and Web of Science using predefined eligibility criteria. A total of 22 studies were included: 17 preclinical studies and five clinical or population-level studies. This represents the largest systematic synthesis of mebendazole evidence in neuro-oncology to date.
The inclusion of both preclinical and clinical data allows the review to bridge the gap between laboratory findings and human evidence — a critical perspective for patients evaluating repurposed drug options.
Preclinical Evidence Across Brain Tumour Types
The preclinical studies included in the review span four major brain tumour categories:
Glioblastoma. The most common and aggressive primary brain tumour in adults. Preclinical studies show mebendazole suppresses glioblastoma growth through multiple mechanisms including microtubule depolymerization, kinase inhibition, and angiogenesis blockade.
Diffuse midline glioma. A highly aggressive paediatric brain tumour with very poor prognosis. Mebendazole demonstrates growth suppression in preclinical models, though the evidence base is smaller than for glioblastoma.
Medulloblastoma. The most common malignant brain tumour in children. Preclinical studies show mebendazole interferes with Hedgehog pathway signaling, a key driver of medulloblastoma pathogenesis.
Meningioma. Typically benign but can become aggressive. Mebendazole shows antiproliferative effects in preclinical meningioma models through disruption of microtubule function.
Mechanisms of Action
The 2026 review identifies six primary mechanisms through which mebendazole exerts anticancer effects in brain tumour models:
| Mechanism | Description | Relevance |
|---|---|---|
| Microtubule depolymerization | Disrupts cellular scaffolding required for cell division | Blocks cancer cell proliferation |
| Kinase inhibition | Suppresses signaling enzymes driving growth | Slows tumour progression |
| Angiogenesis blockade | Prevents formation of new blood vessels | Starves tumours of nutrients |
| Hedgehog pathway interference | Disrupts developmental signaling pathway | Relevant in medulloblastoma |
| Apoptosis/pyroptosis induction | Triggers programmed cell death pathways | Directly kills cancer cells |
| DNA repair impairment | Compromises cancer cell DNA maintenance | Sensitizes to radiotherapy |
Importantly, mebendazole also potentiates standard therapies. The review documents that mebendazole enhances the effects of alkylating agents (such as temozolomide), radiotherapy, and autophagy inhibitors. This synergy suggests mebendazole may be most valuable as an adjunct rather than a standalone therapy.
Formulation and Delivery Challenges
A critical finding of the 2026 review is that mebendazole efficacy is strongly influenced by formulation. The drug exists in multiple polymorphs, and polymorph C demonstrates superior brain penetration and tolerability compared to other forms. This formulation dependency has important implications for both clinical trial design and patient access.
The review also highlights promising delivery strategies to improve CNS exposure:
Efflux inhibition. Combining mebendazole with agents that inhibit P-glycoprotein efflux pumps can increase brain concentration.
Intranasal microemulsions. Nasal delivery bypasses the blood-brain barrier and achieves direct brain uptake.
Nanosuspensions. Nanoparticle formulations improve solubility and may enhance tumour-targeted delivery.
The review explicitly calls for clear formulation reporting in all future clinical trials, noting that inconsistent formulation reporting has hampered interpretation of earlier studies.
Clinical Evidence: Modest and Inconclusive
The five clinical and population-level studies included in the review paint a more cautious picture than the preclinical data. Mebendazole was generally tolerable at high oral doses (up to several grams per day) in early-phase studies, but evidence of meaningful efficacy in brain tumour patients remained modest, inconsistent, and inconclusive.
The review's conclusion is unambiguous: "MBZ shows broad preclinical anticancer activity and acceptable tolerability in early human studies, but current clinical evidence does not demonstrate meaningful efficacy in brain tumour patients." This assessment reflects the well-known challenge of translating preclinical promise into clinical benefit — a pattern seen across many repurposed drug candidates.
Future Directions
The 2026 review outlines several priorities for advancing mebendazole in neuro-oncology:
Well-designed comparative trials. Randomized controlled trials comparing mebendazole plus standard therapy versus standard therapy alone, with adequate sample sizes and follow-up periods.
Clear formulation reporting. All trials must specify the mebendazole polymorph used, as this directly affects bioavailability and brain penetration.
Integrated pharmacokinetic and biomarker analyses. Measuring drug levels in cerebrospinal fluid and tumour tissue, alongside biomarkers of target engagement.
Combination strategy optimization. Identifying which standard therapies (alkylators, radiotherapy, immunotherapy) are most synergistic with mebendazole.
The review authors emphasize that mebendazole remains a scientifically interesting candidate with a strong mechanistic rationale, but its clinical utility in brain tumours requires substantially more evidence.
Frequently Asked Questions
What brain tumour types were studied in the review?
The 2026 systematic review included preclinical studies across glioblastoma, diffuse midline glioma, medulloblastoma, and meningioma. Clinical evidence included early-phase studies in glioblastoma and other primary brain tumours.
What mechanisms does mebendazole use against brain tumours?
Preclinical studies show mebendazole suppresses brain tumour growth through microtubule depolymerization, kinase inhibition, angiogenesis blockade, Hedgehog pathway interference, apoptosis and pyroptosis induction, and impairment of DNA repair. It also potentiates standard therapies including alkylating agents and radiotherapy.
Is mebendazole effective in human brain tumour patients?
Current clinical evidence is modest and inconclusive. The 2026 review found that while mebendazole was generally tolerable at high oral doses in early-phase studies, evidence of meaningful efficacy in brain tumour patients remains limited. Well-designed comparative trials with optimized formulations are needed.
In Plain Terms
Mebendazole is a common anti-parasite medication that scientists are studying as a potential treatment for brain tumours. A 2026 systematic review examined 22 studies and found that in laboratory experiments and animal models, mebendazole consistently slowed the growth of brain tumours including glioblastoma, medulloblastoma, and meningioma. It works through multiple mechanisms: disrupting the cellular scaffolding that helps tumours grow, blocking blood vessel formation that feeds tumours, and triggering cancer cell death. It also appears to make standard treatments like chemotherapy and radiation work better. However, when tested in small human studies, the results were much less clear. The drug was safe at high doses, but there was no strong evidence that it meaningfully helped brain tumour patients. The review concludes that better clinical trials with improved drug formulations are needed before mebendazole can be considered a proven brain tumour therapy.
Shop Sanare Lab
Lab-tested products for patients researching repurposed antiparasitic compounds.
180 capsules — 99% purity, laboratory tested
180 capsules — 99% purity, laboratory tested
Disclaimer: Links are informational and do not constitute medical advice. Always consult a healthcare provider before using any supplement or medication.
References
- From anthelmintic to neuro-oncology: A systematic review of mebendazole repurposing for brain tumour therapy. Br J Clin Pharmacol. 2026;PMID: 42120351. PubMed
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The information about mebendazole is based on systematic review-level evidence. Always consult a qualified healthcare provider before considering any off-label medication use.
Sanare Lab
Science-based health education team reviewing published research on repurposed drugs, integrative oncology, and evidence-based protocols.